Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
Director departure
Appointed director
Inv. presentation
Acq. completed
Consulting agrmnt
Employment agrmnt

Theriva Biologics, Inc. (SYN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
08/16/2023 DEFR14A Form DEFR14A - Revised definitive proxy soliciting materials:
08/15/2023 ARS Form ARS - Annual Report to Security Holders:
08/14/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/11/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "STOCKHOLDERS"
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results"
08/02/2023 8-K Quarterly results
06/08/2023 4 SHALLCROSS STEVEN A (CEO and CFO) has filed a Form 4 on Theriva Biologics, Inc.
Txns: Bought 14,000 shares @ $0.6931, valued at $9.7k
06/07/2023 4 SHALLCROSS STEVEN A (CEO and CFO) has filed a Form 4 on Theriva Biologics, Inc.
Txns: Bought 26,000 shares @ $0.6328, valued at $16.5k
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results"
03/30/2023 10-K Annual Report for the period ended December 31, 2022
03/30/2023 8-K Quarterly results
03/10/2023 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Other Events, F...
02/13/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/03/2023 4 SHALLCROSS STEVEN A (CEO and CFO) has filed a Form 4 on Theriva Biologics, Inc.
Txns: Bought 25,000 shares @ $0.9405, valued at $23.5k
01/26/2023 4 SHALLCROSS STEVEN A (CEO and CFO) has filed a Form 4 on Theriva Biologics, Inc.
Txns: Bought 25,000 shares @ $0.873, valued at $21.8k
01/23/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/17/2023 8-K Quarterly results
01/09/2023 8-K Quarterly results
01/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/23/2022 8-K Quarterly results
12/20/2022 8-K Quarterly results
12/16/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/16/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/16/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/16/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/16/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/09/2022 EFFECT Form EFFECT - Notice of Effectiveness:
12/05/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/05/2022 POS AM Form POS AM - Post-Effective amendments for registration statement:
10/17/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
10/12/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial S...
Docs: "Certificate of Change to Articles of Incorporation",
"Amended and Restated Bylaws",
"Synthetic Biologics Rebrands as Theriva Biologics"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy